Curevac announces positive phase 2 interim data from covid-19 vaccine development program in collaboration with gsk providing strong validation of proprietary technology platform

Head-to-head comparison with licensed bivalent mrna-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile monovalent mrna vaccine candidate, cv0601, encoding omicron ba.4-5 variant and bivalent candidate, cv0701, encoding omicron ba.4-5 variant as well as the original sars-cov-2 virus, successfully boosted antibody titers and were generally well tolerated across all tested dose levels tÜbingen, germany and boston, ma / accesswire / january 5, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced positive interim data from the ongoing phase 2 study assessing monovalent and bivalent modified vaccine candidates against covid-19.
CVAC Ratings Summary
CVAC Quant Ranking